Author:
Moss Joe W. E.,Todd Derick,Grodzicki Lukasz,Palazzolo Beatrice,Mattock Richard,Mealing Stuart,Souter Maxim,Brown Benedict,Bromilow Tom,Lewis Damian,McCready James,Tayebjee Muzahir,Shepherd Ewen,Sasikaran Thiagarajah,Coyle Clare,Ismyrloglou Eleni,Johnson Nicholas A.,Kanagaratnam Prapa
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Health Policy,Pharmacology
Reference39 articles.
1. National Clinical Guideline Centre. Atrial fibrillation: diagnosis and management. 2021. https://www.nice.org.uk/guidance/ng196.
2. Mann I, Sasikaran T, Sandler B, Babalis D, Johnson N, Falaschetti E, et al. Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation (AVATAR-AF): design and rationale. Am Heart J. 2019;214:36–45. https://doi.org/10.1016/j.ahj.2019.04.015.
3. Kanagaratnam P, McCready J, Tayebjee M, Shepherd E, Sasikaran T, Todd D, et al. Ablation versus anti-arrhythmic therapy for reducing all hospital episodes from recurrent atrial fibrillation: a prospective, randomized, multi-centre, open label trial. EP Europace. 2023;25(3):83–872. https://doi.org/10.1093/europace/euac253.
4. National Institute for Health and Care Excellence. NICE health technology evaluations: the manual. 2022. https://www.nice.org.uk/process/pmg36.
5. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708–15. https://doi.org/10.1016/j.jval.2012.02.008.